What do systematic reviews say?

Antidepressants vs placebo

• Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 511 participants
  Very low

Antidepressants vs placebo

It is very uncertain whether antidepressants changes efficacy as a dichotomous outcome compared with placebo (very low certainty).

• Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
  RR 0.74 [0.57, 0.96]
  7 studies · 662 participants
  Very low

Antidepressants vs placebo

It is very uncertain whether antidepressants changes dropouts due to any cause (acceptability) compared with placebo (very low certainty).

• Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
  RR 0.85 [0.52, 1.38]
  9 studies · 479 participants
  Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

• Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 237 participants
  Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCAs) (very low certainty).

• Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
  RR 1.1
  2 studies · 199 participants
  Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty).

• Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
  RR 0.83 [0.53, 1.3]
  3 studies · 237 participants
  Very low

Mirtazapine vs tricyclic antidepressants (TCAs)

• Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Very low

Mirtazapine vs tricyclic antidepressants (TCAs)

It is very uncertain whether mirtazapine changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCA) (very low certainty).

• Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
  RR 0.81 [0.6, 1.09]
  1 study · 33 participants
  Very low

Mirtazapine vs tricyclic antidepressants (TCAs)

It is very uncertain whether mirtazapine changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCA) (very low certainty).

• Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
  RR 0.65 [0.2, 2.15]
  1 study · 33 participants
  Very low